SCHEMBL21023740

SCHEMBL21023740

CC(=N)/C=C(/NC(=S)NC(=O)c1ccc(Cl)cc1)NC1CCCC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.54
NPC1 O15118 8/20 0.50
RAB9A P51151 7/20 0.50
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.43
ALDH1A1 P00352 6/20 0.43
ALOX12 P18054 4/20 0.43
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
HTT P42858 1/20 0.43
LMNA P02545 3/20 0.42
KCNH2 Q12809 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
CYP1A2 P05177 1/20 0.40
HPGD P15428 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14865782 0.80 EPHX1 (0.76) EPHX1NPC1RAB9AKMT2AMEN1
SCHEMBL12196200 0.71 EPHX1 (1.00) EPHX1NPC1RAB9AKMT2AMEN1
SCHEMBL8303337 0.70 EPHX1 (0.77) EPHX1NPC1RAB9AKMT2AMEN1
SCHEMBL14860025 0.70 NPC1 (0.74) EPHX1NPC1RAB9AKMT2AMEN1
SCHEMBL29779494 0.70 SMN1; SMN2 (0.65) EPHX1NPC1RAB9AKMT2AMEN1
SCHEMBL2351318 0.68 RAB9A (0.70) EPHX1NPC1RAB9AKMT2AMEN1
SCHEMBL21741924 0.67 NPC1 (0.68) EPHX1NPC1RAB9AKMT2AMEN1
SCHEMBL16587394 0.67 RAB9A (1.00) NPC1RAB9AKMT2AMEN1POLB
SCHEMBL16108484 0.67 RAB9A (1.00) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1604644 0.67 RAB9A (1.00) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3080087-B1 N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORP (US) 2019-05-22 EP disclosed